Loading icon
Press enter or spacebar to select a desired language.
Research
Press enter or spacebar to select a desired language.

PubMed COVID-19 Clinical Care

35171 - 35180 of 57753 results found

Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study

Date
Thursday, July 06, 2023 - 4:00 AM
Description
BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy is a promising option for patients with heavily treated multiple myeloma. Point-of-care manufacturing can increase the availability of these treatments worldwide. We aimed to assess the